Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 28Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 10Brain Neoplasms 7Skin Neoplasms 6Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Mesothelioma 3Liver Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Glioblastoma 2Colonic Neoplasms 2

Interventions

serabelisib 1sapanisertib 1Specimen Handling 1Restraint, Physical 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Endometrioid × Ipilimumab × Clear all
NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡